Posted by Michael Wonder on 20 May 2021
Patients with rare blood disorders to receive new treatment option, says NICE
20 May 2021 - Hundreds of people with two rare blood disorders will soon have access to a new treatment regimen following guidance from NICE.
In final guidance published today, NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria.
Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome.
